Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma - Takeaways - MDSpire

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

  • By

  • Amit Kumar Mitra

  • Ujjal Kumar Mukherjee

  • Suman Mazumder

  • Vithal Madhira

  • Timothy Bergquist

  • Yu Raymond Shao

  • Feifan Liu

  • Qianqian Song

  • Jing Su

  • Shaji Kumar

  • Benjamin A. Bates

  • Noha Sharafeldin

  • Umit Topaloglu

  • December 7, 2023

  • 0 min

Share

  • 1

    COVID-19 has significantly impacted mortality and quality of life globally, particularly among cancer patients.

  • 2

    Patients with multiple myeloma have compromised immune systems, increasing their risk for severe COVID-19 outcomes.

  • 3

    The National COVID Cohort Collaborative (N3C) provides a large dataset for studying COVID-19 effects on myeloma patients.

  • 4

    The study identifies bone marrow transplantation and SARS-CoV-2 vaccination as protective factors against COVID-19 severity.

  • 5

    Myeloma patients experience higher inpatient mortality rates due to COVID-19, necessitating further research on treatment impacts.

Original Source(s)

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

  • by Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin A. Bates, Noha Sharafeldin, Umit Topaloglu

  • December 7, 2023

Related Content

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min
Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research